SM

Sosei Heptares is a world-leading biopharmaceutical group focused on the discovery and early development of G protein-coupled receptor (GPCR) focused therapies. The company utilizes its proprietary StaR (Stabilized Receptor) technology and structure-based drug design (SBDD) platform to build a diverse pipeline of small molecules and biologics across multiple therapeutic areas, including neurology, immunology, and gastroenterology. Sosei Heptares has established numerous high-value partnerships with major pharmaceutical companies such as AbbVie, Genentech, GSK, and Eli Lilly. Following the acquisition of Idorsia's pharmaceuticals business in Japan and South Korea, the company has transitioned into a fully integrated biopharmaceutical entity with commercial capabilities in the Asia-Pacific region.